Indication
Aggressive NK Cell Leukemia
2 clinical trials
2 products
Clinical trial
A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasStatus: Recruiting, Estimated PCD: 2024-12-01
Product
DR-01Clinical trial
Multicenter, Open-label, Dose-escalation Phase I/II Study to Evaluate the Tolerability, Safety, Efficacy and Pharmacokinetics of Repeated Continuous Intravenous PPMX-T003 in Patients With Aggressive NK Cell Leukaemia (ANKL) (Physician-initiated Clinical Trial)Status: Recruiting, Estimated PCD: 2025-03-31
Product
PPMX-T003